Validation of an amino-acid-based radionuclide therapy plus external beam radiotherapy in heterotopic glioblastoma models

Nuclear Medicine and Biology

Volumn 38, Issue 4, 2011, Pages 451-460

  Israel, Ina ^a   Blass, Georg ^b   Reiners, Christoph ^a   Samnick, Samuel ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

H2AX foci; Amino acid transport; External radiotherapy; Malignant gliomas; Radionuclide therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BISBENZIMIDE; HISTONE H2AX; PHENYLALANINE I 131; PROPIDIUM IODIDE; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CLONOGENIC ASSAY; DNA DAMAGE; DNA REPAIR; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHOTON THERAPY; RADIATION DOSE; RADIOSENSITIVITY; RAT; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; HUMANS; IODINE RADIOISOTOPES; MICE; PHENYLALANINE; RADIOTHERAPY; RATS; TRANSPLANTATION, HETEROTOPIC;

EID: 79955464867     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.12.002     Document Type: Article

References (36)

1. DeAngelis L.M. Brain tumors. N Engl J Med 2001, 344:114-123.
2. Surawicz T.S., Davis F., Freels S., Laws E.R., Menck H.R. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 1998, 40:151-160.
3. Rainov N., Ren H. Clinical trials with retrovirus mediated gene therapy - what have we learned?. J Neurooncol 2003, 65:227-236.
4. Bowers G., He J., Schulz K., Olivarria G., Maneval D., Olson J.J. Efficacy of adenoviral p53 delivery with SCH58500 in the intracranial 9l and RG2 models. Front Biosci 2003, 8:54-61.
5. Friese M.A., Platten M., Lutz S.Z., et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003, 63:8996-9006.
6. Riva P., Franceschi G., Riva N., Casi M., Santimaria M., Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 2000, 27:601-609.
7. Olzowy B., Hundt C.S., Stocker S., Bise K., Reulen H.J., Stummer W. Photoirradiation therapy of experimental malignant glioma with 5-aminolevulinic acid. J Neurosurg 2002, 97:970-976.
8. Perkins E., Calvert J., Lancon J.A., Parent A.D., Zhang J. Inhibition of H-ras as a treatment for experimental brain C6 glioma. Brain Res Mol Brain Res 2003, 1:42-51.
9. Stummer W., Stocker S., Novotny A., et al. In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. J Photochem Photobiol 1998, 45:160-169.
10. Quang T.S., Brandy L.W. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 2004, 58:972-975.
11. Jager P.L., Vaalburg W., Pruim J., de Vries E.G., Langen K.J., Piers D.A. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001, 42:432-445.
12. Pauleit D., Floeth F., Hamacher K., et al. O-(2-[18F]fluoroethyl)-l-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005, 128:678-687.
13. Samnick S., Bader J.B., Hellwig D., et al. Clinical value of iodine-123-α-methyl-l-tyrosine single photon emission tomography in the differential diagnosis of recurrent brain tumor in patients pretreated for glioma at follow-up. J Clin Oncol 2002, 20:396-404.
14. Van der Borght T., Asenbaum S., Bartenstein P., et al. EANM procedure guidelines for brain tumour imaging using labelled amino analogues. Eur J Nucl Med Mol Imaging 2006, 33:1374-1380.
15. Samnick S., Richter S., Romeike B.F., et al. Investigation of iodine-123-labelled amino acid derivatives for imaging cerebral gliomas: uptake in human glioma cells and evaluation in stereotactically implanted C6 glioma rats. Eur J Nucl Med 2000, 27:1543-1551.
16. Samnick S., Hellwig D., Romeike B.F., Moringlane J.R., Feiden W., Kirsch C.M. Initial evaluation on the feasibility of single photon emission tomography with l-p-[123I]iodo-phenylalanine for routine brain tumor imaging. Nucl Med Commun 2002, 23:121-130.
17. Fuchs B.C., Bode B.P. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?. Semin Cancer Biol 2005, 15:254-266.
18. Miyagawa T., Oku T., Uehara H., Desai R., Beattie B., Tjuvajev J., et al. "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 1998, 18:500-509.
19. Langen K.J., Bröer S. Molecular transport mechanisms of radiolabeled amino acids for PET and SPECT. J Nucl Med 2004, 45:1435-1436.
20. Hellwig D., Ketter R., Romeike B.F., et al. Validation of brain tumour imaging with p-[123 I]iodo-l-phenylalanine and SPECT. Eur J Nucl Med Mol Imaging 2005, 32:1041-1049.
21. Hellwig D., Romeike B.F., Ketter R., Moringlane J.R., Kirsch C.M., Samnick S. Intra- individual comparison of p-[(123)I]-iodo-l-phenylalanine and l-3-[ (123)I]-iodo-alpha-methyl-tyrosine for SPECT imaging of gliomas. Eur J Nucl Med Mol Imaging 2008, 35:24-31.
22. Romeike B.F., Hellwig D., Heimann A., Kempski O., Feiden W., Kirsch C.M., et al. Action and efficacy of p-[131I]iodo-l-phenylalanine on primary human glioma cell cultures and rats with C6-gliomas. Anticancer Res 2004, 24:3971-3976.
23. Samnick S., Romeike B.F., Lehmann T., Israel I., Rübe C., Mautes A., et al. Efficacy of systemic radionuclide therapy with p-[131I]iodo-l-phenylalanine combined with external beam photon irradiation in treating malignant gliomas. J Nucl Med 2009, 50:2025-2032.
24. Candolfi M., Curtin J.F., Nichols W.S., et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 2007, 85(2):133-148.
25. Israel I., Brandau W., Farmakis G., Samnick S. Improved synthesis of no-carrier-added p-[124I]iodo-l-phenylalanine and p-[131I]iodo-l-phenylalanine for nuclear medicine applications in malignant gliomas. Appl Radiat Isot 2008, 66:513-522.
26. Schäfer T., Scheuer C., Roemer K., Menger M.D., Vollmar B. Inhibition of p53 protects liver tissue against endotoxin-induced apoptosis and necrotic cell death. FASEB J 2003, 17:660-667.
27. Lassmann M., Hänscheid H., Gassen D., Biko J., Meineke V., Reiners C., et al. In vivo formation of γ-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2010, 51(8):1318-1325.
28. Hellwig D., Menges M., Schneider G., et al. Radioiodinated phenylalanine derivatives to image pancreatic cancer: a comparative study with [18F]fluoro-2-deoxy-d-glucose in human pancreatic carcinoma xenografts and in inflammation models. Nucl Med Biol 2005, 32:137-145.
29. Schütze C., Bergmann R., Yaromina A., et al. Effect of increased of radiation dose on local control relates to pretreatment FDG uptake in FaDu tumours in nude mice. Radiother Oncol 2007, 83:311-315.
30. Weppler S.A., Krause M., Zyromska A., Lambin P., Baumann M., Wouters B.G. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol 2007, 82:96-104.
31. Msirikale J.S., Klein J.L., Schroeder J., Order S.E. Radiation enhancement of radiolabelled antibody deposition in tumors. Int J Radiat Oncol Biol Phys 1987, 13:1839-1844.
32. Knox S.J., Sutherland W., Goris M.L. Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobological parameters. Radiat Res 1993, 135:24-31.
33. Mahrhofer H., Bürger S., Oppitz U., Flentje M., Djuzenova C.S. Radiation induced DNA, damage and damage repair in human tumor and fibroblast cell lines assessed by histone H2AX phosphorylation. Int J Radiat Oncol Biol Phys 2006, 64:573-580.
34. Hellwig D., Gouverneur E., Schaefer A., et al. Para-[123I]iodo-l-phenylalanine in patients with pancreatic adenocarcinoma. Tumour uptake, whole-body kinetics, dosimetry. Nuklearmedizin 2008, 47:220-224.
35. Gouverneur E., Hellwig D., Schaefer A., et al. Tumour uptake, whole-body kinetics and dosimetry of I-123-, I-124- and I-131-labeled p-iodo-l-phenylalanine in patients with pancreatic adenocarcinoma. Eur J Nucl Med Mol Imaging 2008, 35(supl):S171.
36. Barone R., Borson-chazot F., Valkema R., et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005, 46:99S-106S.